Inloggad som:
CLL18
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
CLL18
CLL18/MOIRAI - En fas 3 multicenter, randomiserad, prospektiv, öppen studie av tidsbestämd (12 cykler) venetoclax/obinutuzumab vs. tidsbestämd (15 cykler) venteoclax/pirtobrutinib vs. MRD-styrd venetoclax/pirtobrutinib för patienter med tidigare obehandlad kronisk lymfatisk leukemi (KLL)/småcelligt lymfocytiskt lymfom (SLL), med användande av MRD-analys av kvarvarande sjukdom för individuellt anpassad tidsbegränsad behandling
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes
PLACEHOLDER
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/
obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/
pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/
small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for
adjustment of treatment duration to improve outcomes
Mer information om studien för vårdgivare
1. Documented CLL/SLL requiring treatment according to iwCLL criteria73 with a CLL phenotype
cell count >10-2 tracked by flow cytometry at screening. (för mer info se länk)
1. Any prior CLL- or SLL-specific therapies1, except for corticosteroid treatment administered due
to necessary immediate intervention (within the last 10 days before start of study treatment only
dose equivalents up to 20 mg prednisolone per day are permitted). (för mer info se länk)
Behandling
Fas 3
Kurativ
Ej tillämpbar
Akademisk
Studien ändrades senast: (2025-10-02)